ATYR
Income statement / Annual
Last year (2023), aTyr Pharma, Inc.'s total revenue was $353,000.00,
a decrease of 96.60% from the previous year.
In 2023, aTyr Pharma, Inc.'s net income was -$50.39 M.
See aTyr Pharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$353,000.00
|
$10.39 M
|
$0.00
|
$10.46 M
|
$422,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$2.74 M |
$1.70 M |
$1.30 M |
$17.29 M |
$14.05 M |
$746,000.00 |
$713,000.00 |
$900,000.00 |
| Gross Profit |
-$2.39 M |
$8.69 M |
-$1.30 M |
-$6.84 M |
-$13.63 M |
-$746,000.00 |
-$713,000.00 |
-$900,000.00 |
| Gross Profit Ratio |
-6.76 |
0.84 |
0 |
-0.65 |
-32.29 |
0 |
0 |
0 |
| Research and Development
Expenses |
$42.29 M
|
$42.81 M
|
$23.26 M
|
$17.29 M
|
$14.05 M
|
$20.39 M
|
$30.07 M
|
$44.25 M
|
| General & Administrative
Expenses |
$12.98 M
|
$13.98 M
|
$10.75 M
|
$9.08 M
|
$9.35 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
-$1.70 M
|
-$1.30 M
|
-$1.27 M
|
-$1.37 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.98 M
|
$12.29 M
|
$9.45 M
|
$7.81 M
|
$7.99 M
|
$11.69 M
|
$16.36 M
|
$14.19 M
|
| Other Expenses |
$0.00 |
$1.06 M |
$238,000.00 |
-$319,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$12.98 M |
$55.10 M |
$32.71 M |
$25.10 M |
$22.03 M |
$32.07 M |
$46.43 M |
$58.44 M |
| Cost And Expenses |
$55.27 M |
$56.79 M |
$34.02 M |
$26.37 M |
$23.40 M |
$32.82 M |
$47.15 M |
$59.34 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$65,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.74 M
|
$1.70 M
|
$1.30 M
|
$1.27 M
|
$1.37 M
|
$746,000.00
|
$713,000.00
|
$900,000.00
|
| EBITDA |
-$52.18 M
|
-$44.71 M
|
-$32.47 M
|
-$14.65 M
|
-$21.61 M
|
-$32.07 M
|
-$46.43 M
|
-$57.00 M
|
| EBITDA Ratio |
-147.81 |
-4.3 |
0 |
-1.4 |
-51.21 |
0 |
0 |
0 |
| Operating Income Ratio
|
-155.58
|
-4.47
|
0
|
-1.52
|
-54.45
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.52 M
|
$1.06 M
|
$238,000.00
|
-$319,000.00
|
-$785,000.00
|
-$1.70 M
|
-$1.06 M
|
$1.44 M
|
| Income Before Tax |
-$50.40 M |
-$45.34 M |
-$33.78 M |
-$16.23 M |
-$23.76 M |
-$34.52 M |
-$48.21 M |
-$57.90 M |
| Income Before Tax Ratio
|
-142.77
|
-4.37
|
0
|
-1.55
|
-56.31
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$5,000.00 |
-$9,000.00 |
-$6,000.00 |
-$160,000.00 |
$1.00 |
$0.00 |
-$49,000.00 |
| Net Income |
-$50.39 M |
-$45.34 M |
-$33.77 M |
-$16.22 M |
-$23.60 M |
-$34.52 M |
-$48.21 M |
-$57.86 M |
| Net Income Ratio |
-142.75 |
-4.37 |
0 |
-1.55 |
-55.93 |
0 |
0 |
0 |
| EPS |
-0.94 |
-1.6 |
-1.77 |
-1.77 |
-7.03 |
-16.13 |
-26.16 |
-34.2 |
| EPS Diluted |
-0.94 |
-1.6 |
-1.77 |
-1.77 |
-7.03 |
-16.13 |
-26.16 |
-34.2 |
| Weighted Average Shares
Out |
$53.61 M
|
$28.42 M
|
$19.08 M
|
$9.16 M
|
$3.36 M
|
$2.14 M
|
$1.84 M
|
$1.69 M
|
| Weighted Average Shares
Out Diluted |
$53.61 M
|
$28.42 M
|
$19.08 M
|
$9.16 M
|
$3.36 M
|
$2.14 M
|
$1.84 M
|
$1.69 M
|
| Link |
|
|
|
|
|
|
|
|
